| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Departments of Pediatric Dentistry and Microbiology, Immunobiology Vaccine Center, University of Alabama at Birmingham, Birmingham, AL 35294;
Laboratory of Veterinary Epidemiology, Graduate School of Agriculture and Biological Sciences, Osaka Prefecture University, Sakai-shi, Osaka, Japan;
Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717;
Department of Pathology, Medical Center, Duke University, Durham, NC 27710; and
¶ Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute for Medical Sciences, University of Tokyo, Tokyo, Japan
The threat posed by botulism, classically a food- and waterborne disease with a high morbidity and mortality, has increased exponentially in an age of bioterrorism. Because botulinum neurotoxin (BoNT) could be easily disseminated by terrorists using an aerosol or could be used to contaminate the food or water supply, the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases has classified it as a category A agent. Although clearly the development of a safe and effective mucosal vaccine against this toxin should be a high priority, essentially no studies to date have assessed mucosal immune responses to this disease. To bridge this gap in our knowledge, we immunized mice weekly for 4 wk with nasal doses of BoNT type A toxoid and a mutant of cholera toxin termed E112K. We found elevated levels of BoNT-specific IgG Abs in plasma and of secretory IgA Abs in external secretions (nasal washes, saliva, and fecal extracts). When mice given nasal BoNT vaccine were challenged with 4 x 103 LD50 of BoNT type A (BoNT/A) via the i.p. route, complete protection was seen, while naive mice given the same dosage died within 2 h. To further confirm the efficacy of this nasal BoNT vaccine, an oral LD50 was determined. When mice were given an oral challenge of 5 µg (2 x oral LD50) of progenitor BoNT/A, all immunized mice survived beyond 5 days, while nonimmunized mice did not. The fecal extract samples from nasally vaccinated mice were found to contain neutralizing secretory IgA Abs. Taken together, these results show that nasal BoNT/A vaccine effectively prevents mucosal BoNT intoxication.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  T. Nochi, Y. Yuki, A. Matsumura, M. Mejima, K. Terahara, D.-Y. Kim, S. Fukuyama, K. Iwatsuki-Horimoto, Y. Kawaoka, T. Kohda, et al. A novel M cell specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses J. Exp. Med., November 26, 2007; 204(12): 2789 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ravichandran, F. H. Al-Saleem, D. M. Ancharski, M. D. Elias, A. K. Singh, M. Shamim, Y. Gong, and L. L. Simpson Trivalent Vaccine against Botulinum Toxin Serotypes A, B, and E That Can Be Administered by the Mucosal Route Infect. Immun., June 1, 2007; 75(6): 3043 - 3054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kataoka, K. Fujihashi, S. Sekine, T. Fukuiwa, R. Kobayashi, H. Suzuki, H. Nagata, K. Takatsu, S. Shizukuishi, J. R. McGhee, et al. Nasal Cholera Toxin Elicits IL-5 and IL-5 Receptor {alpha}-Chain Expressing B-1a B Cells for Innate Mucosal IgA Antibody Responses J. Immunol., May 15, 2007; 178(10): 6058 - 6065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maddaloni, H. F. Staats, D. Mierzejewska, T. Hoyt, A. Robinson, G. Callis, S. Kozaki, H. Kiyono, J. R. McGhee, K. Fujihashi, et al. Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A J. Immunol., October 15, 2006; 177(8): 5524 - 5532. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
